Anthroposophic Pharmacy

Last update: 28.08.2020

Anthroposophic medicinal products are made from raw materials of natural origin, i.e., they are primarily taken from nature. The raw materials include minerals, metals, plants and partial plants, eusocial insects, animal organs and organ derivatives.

Today the pharmaceutical processes of Anthroposophic Pharmacy are well described in the European Pharmacopoeia (Pharmacopoea Europaea), the German Homoeopathic Pharmacopoeia (HAB), the Swiss Pharmacopoeia (Pharmacopoea Helvetica) and the Anthroposophic Pharmaceutical Codex (APC). The APC presents all relevant processes of Anthroposophic Pharmacy in one work.

Many anthroposophic medications are on the market based on specific national legislation. In the European Union, anthroposophic medications are generally regulated according to Directive 2001/83/EC. The Directive mentions anthroposophic medicinal products only in its introductory paragraphs (paragraph 22) and defines that, provided the products are prepared according to the homeopathic method, they should be regulated as homeopathic medicinal products.

The origin, production and application of anthroposophic medicinal products go back to Rudolf Steiner (1861–1925), who founded Anthroposophic Medicine at the beginning of the 20th century together with the physician Ita Wegman (1876–1943). At that time Rudolf Steiner developed principles for the choice of raw materials and the various manufacturing processes that are still valid today. Another pioneer of Anthroposophic Pharmacy was Rudolf Hauschka (1891–1969).

Research news

Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions 
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of ceratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research
https://doi.org/10.1159/000537979.


Further information on Anthroposophic Medicine